natgillin/translations-raw huggingface dataset:
Preferably, the micropores, mesopores and/or macropores can interconnect. 
Biološki razgradivi kompozitni materijal prema zahtjevu 6, naznačen time, da se mikropore, mezopori i/ili makropore međusobno povezuju.
Preferred polyglycols are polyethylene glycol or polypropylene glycol. 
Poželjni poliglikoli su polietilen glikol ili polipropilen glikol.
Another beagle dog given the same dose of 42-O-(D-fructosylcarbonyl)rapamycin showed no overt physical changes and maintained a normal food intake. 
Drugom beagle psu dana je ista doza 42-0-(D-fruktozilkarbonil)rapamicina i nije pokazao nikakvih vidljivih fizičkih promjena te je zadržao normalan unos hrane.
Add chlorotrimethylsilane (24.0 mL, 190.0 mmol) dropwise, maintaining an internal temperature <5° C. Continue stirring at 0° C. for 2 hours. In a separate flask, dissolve 2-propylpentanoic acid (6.0 g, 41.8 mmol) in anhydrous acetonitrile (100 mL). 
Ukapa se klortrimetilsilan (24,0 ml, 190,0 mmol), uz održavanje unutarnje temperatura ispod 5 "C. 5 miješanjem se nastavi još 2 sata na 0 "C. U odvojenoj tikvici otopi se 2-propilpentanska kiselina (6,0 g, 41,8 mmol) u bezvodnom acetonitrilu (100 ml).
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Preferably the tumor is selected from the group of: sarcoma, carcinoma, carcinoid, bone tumor or neuroendocrine tumor. 
Peptid u skladu s patentnim zahtjevom 12, naznačen time što se tumor bira iz skupine koju čine: sarkom, karcinom, karcinoid, tumor kostiju ili neuroendokrini tumor.
In an opened state of the extraction module the jaw members are distanced from each other. 
U otvorenom položaju modula za ekstrakciju elementi čeljusti su razmaknuti jedan od drugoga.
A suspension of 2-amino thiazole (16 mmol) and pyridine (16 mmol) in 1,2-dichloroethane (20 mL) was added portion wise. 
Suspenzija od 2-amino tiazola (16 mmol) i piridina (16 mmol) se u obrocima dodaje u 1,2-dikloroetan (20 ml).
The method of claim 13 or 14, wherein the aliphatic polycarbonate comprises poly(propylene carbonate). 
Postupak u skladu s patentnim zahtjevima 13 ili 14, naznačen time, da alifatski polikarbonat sadržava poli(propilen karbonat).
In the above connection, it is also recommended, in order to prevent subsequent contamination of the groove structures 4, that the filling medium is not removed until cleaning has been carried out following mechanical machining, including the separation operation. 
U svezi gore iznesenog, a da se spriječi kasnije onečišćenje brazdastih struktura 4, također se preporuča, da se punilo ne odstranjuje prije provedbe čišćenja nakon mehaničke strojne obrade, koja uključuje i postupak odvajanja.
Formulation according to claim 6, wherein the buffer solution is an aqueous citrate buffer. 
Formulacija u skladu s patentnim zahtjevom 6, naznačena time što puferska otopina je vodeni citratni pufer. t>&
The composition of clause 15 wherein said cyclodextrin is B-cyclodextrin or a derivative thereof. 
B-ciklodekstrin ili derivat istog, poželjno hidroksipropil B-ciklodekstrin ili sulfobutileter B-ciklodekstrin.
Process (d) removal of a protecting group from a quinazoline derivative of Formula I, or a pharmaceutically acceptable salt thereof; 
Postupak (d) uklanjanje zaštitne skupine sa derivata kinazolina prikazanog Formulom I, ili njegove farmaceutski prihvatljive soli.
A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 4 and, optionally, an effective amount of another therapeutic agent. A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient. 
Upotreba prema zahtjevu 40, naznačena time da lijek sadrži učinkovitu količinu drugog terapeutskog agensa. Metoda inhibicije funkcije VRI u stanici in vitro koja sadrži dolaženje u kontakt sa stanicom, koja može eksprimirati VR1 s učinkovitom količinom spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20. Oprema koja sadrži spremnik koji sadrži učinkovitu količinu spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
It relates particularly to insulating containers for hot drinks or the like. 
On se naročito odnosi na izolirane spremnike za vruće napitke Ui tome slično i na postupak za proizvodnju takvih spremnika.
An acylthiourea compound represented by formula (I): 
Spoj aciltiouree prema formuli (1):
The preparation according to claim 18, characterised by that said textile is made of the oxidised cellulose, polyamide PAD, polypropylene PP or another suitable polymer not exhibiting an adhesion to the wound, or a mixture thereof 
Pripravak prema zahtjevu 18, naznačen time da je navedeni tekstilni materijal izrađen od oksidirane celuloze, poliamida PAD, polipropilena PP ili drugog pogodnog polimera koji ne iskazuje svojstvo lijepljenja na ranu, ili od njihove smjese.
In another preferred aspect thereof, the present invention provides a pharmaceutical composition according to claim 1, comprising at least two peptides, wherein said peptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 10, or SEQ ID NO: 12 to SEQ ID NO: 23; provided that the composition comprises at least one peptide comprising SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 12 or SEQ ID NO: 13 or a variant or salt thereof; and further comprising mannitol and poloxamer 188, wherein the ratio by weight of peptides to mannitol to poloxamer 188 is in the range including and between 1:5:1.5 to 1:8:2.2. 
L IL. Farmaceutski sastav koji uključuje najmanje dva peptida, naznačeno time da se spomenuti peptidi sastoje od slijeda aminokiselina odabranih u skupini koja se sastoji od SEQ ID BR: 1 do SEQ ID BR: 11 pod uvjetom da sastav uključuje najmanje jedan peptid koji se sastoji od SEQ ID NO:1 ili SEQ ID NO:2 ili varijante ili soli spomenutih peptida, te da peptid nije dugolančani polipeptid pridružen humanom tumoru i nadalje, da se sastoji od manitola i poloksamera 188, naznačeno time da je maseni udio peptida u odnosu na manitol i poloksamer 188 u rasponu od 1:5:1,5 do 1:8:2,2.
In some embodiments the metabolic-related disorder is coronary heart disease. 
U nekim oblicima metabolički pripadajući poremećaj je koronarno srčano oboljenje.
The molecule for the use according to claim 1 wherein the treatment comprises administration of the CTLA4 mutant molecule at a dosage of 10 mg/kg weight of the subject on days 1, 15, 29, 57, 85 and at a dosage of 5mg/kg weight of the subjectmonthly thereafter. 
Molekula za primjenu u skladu sa patentnim zahtjevom 1 gdje liječenje sadrži administraciju CTLA4 mutirane molekule pri dozi od 10 mg/kg mase subjekta na dane 1, 15, 29, 57, 85 i pri dozi od 5mg/kg mase subjekta mjesečno nakon toga.
The alkylation according to method 1 is conveniently performed in an organic solvent such as a suitably boiling alcohol or ketone, preferably in the presence of an organic or inorganic base (potassium carbonate, diisopropylethylamine or triethylamine) at reflux temperature. 
Alkilacija u skladu s metodom 1 prikladno se vrši u organskom otapalu kao što je to odgovarajući kipući alkohol ili keton, po mogućnosti u prisutnosti jedne organske ili anorganske baze (kalijev karbonat diizopropiletilamin ili trietilamin) na refluks temperaturi.
Structure according to claim 19, characterized in that it comprises holes formed in the containers (12c) of said platforms (10), in which holes pipes are inserted to which a refrigeration or heating fluid is fed in order to directly heat or cool the earth contained in said containers (12c). 
Konstrukcija prema zahtjevu 18, naznačena time, da ona obuhvaća rupe ostvarene u posudama (12c) od navedenih platformi (10), dok su u tim rupama umetnute cijevi koje se pune fluidom za hlađenje ili grijanje, kako bi se izravno grijala ili hladila zemlja u spomenutim posudama (12c).
recovering at least a portion of the culture supernatant, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 30 mU/µg rVWF. 
Pripravak koji sadrži rekombinantni Von Willebrand faktor (rVWF) koji ima specifičnu kofaktornu aktivnost ristocetina od najmanje 80 mU/µg, pri čemu se pripravak može dobiti postupkom koji sadrži sljedeće korake:
Stirring was continued for 1 h at −78° C. Chlorotrimethylsilane (31.5 ml, freshly destilled from CaH) was added and the temperature was allowed to rise to room temperature. 
S miješanjem se nastavi još 1 sat na -78 *C. Doda se klortrimetilsilan (31,5 ml, svježe destiliran iz CaH), te ostavi da temperatura poraste do sobne.
A composition according to claim 12, for use in the treatment of type II diabetes or obesity. 
Kompozicija prema patentnom zahtjevu 12, za uporabu u liječenju dijabetesa tipa II 1li pretilosti.
A cylindrical object wrapped in a protective wrapping according to claim 15, wherein the protective wrapping can be unwrapped in one single piece. 
Valjkasti objekt umotan u zaštitni omotač u skladu s patentnim zahtjevom 12, naznačen time što se zaštitni omotač može razmotati u jednom cijelom komadu.
A composition according to claim 10 optionally, further comprising an antidepressant agent. 
Pripravak prema zahtjevu 24, koji se nadalje sastoji od antidepresivnog agensa.
separating the trans-(+)-A9-tetrahydrocannabinol from the alcoholic-caustic phase; and 
separaciju trans-(+)-A9-tetrahidrokanabinola od alkoholno-kaustične faze; i
The combination of claim 1, wherein the antisense oligonucleotides are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. 
Protusmisleni oligonukleotid ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 9, naznačen time što je oligonukleotid kemijski vezan na jednu ili više skupina ili konjugata koji poboljšavaju aktivnost, staničnu raspodjelu, ili stanični unos protusmislenog oligonukleotida.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(o-tolylthio)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(o-toliltio)izoftalonitril.
The sulfonylureas (SU) are drugs which promote secretion of insulin from pancreatic B cells by transmitting signals of irisulin secretion via SU receptors in the cell membranes. 
Sulfonilree (SE) su lijekovi koji potiču sekreciju inzulina iz B-stanica pankreasa slajem signala sekrecije inzulina via SU receptora u staničnim membranama.
The boom mountable robotic arm of claim 1 wherein said at least one electrically insulated support post includes an insulated upright portion and a riser portion, said riser portion having a first end pivotably connected to said rigid member and a second end supporting said insulated upright portion, and wherein an actuator angularly extends from said second end of said riser portion to said rigid member. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 1, naznačena time, da navedeni električno izolirani podupirač uključuje izolirani uspravni dio 1 podizni dio, gdje navedeni podizni dio ima prvi kraj stožerno spojen na navedeni gornji gredni sklop te drugi kraj koji pridržava navedeni izolirani uspravni dio, te se pritom aktivator proteže pod kutom iz navedenog drugog kraja od navedenog podiznog dijela prema navedenom gornjem grednom sklopu.
The harness may be shaped to surround peripheral parts of said headwear member. 
Slušalice prema zahtjevu 23, naznačene time, da je navedena tehnička oprema oblikovana tako, da opkoljava periferne dijelove od navedene školjke za uho.
In another embodiment, the salt in the pH buffered saline solution comprises magnesium chloride, potassium chloride, sodium chloride or a combination thereof. 
Formulacija u skladu s patentnim zahtjevom 21, naznačena time što sol u fiziološkoj otopini s puferiranim pH sadrži natrijev klorid.
A winder unit (1) in accordance with any preceding claim, wherein, in set up, the cutting wire passes through the bonding material at a position substantially directly below the wire winder unit. 
Jedinica za namatanje, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što, u radnim uvjetima, žica za rezanje prolazi kroz materijal za vezanje na položaju koji je uglavnom odmah ispod jedinice za namatanje žice.
verifying which one among the third and the fourth code matches with the first code stored in the first memory; and 
- - Verifikaciju petog i šestog koda kako bi se utvrdilo koji odgovara prvom kodu pohranjenom u prvoj memoriji; i
The pharmaceutical composition of any one of claims 1 to 5, wherein the carrier is selected from the group consisting of polyols, sugars, sugar alcohols, cellulose, calcium phosphate salts, amino acids and mixture thereof; preferably wherein the carrier is selected from the group consisting of microcrystalline cellulose, trehalose, inositol, L-proline in anhydrous form, anhydrous dibasic calcium phosphate, lactose anhydrous, lactose monohydrate, isornalt, mannitol or mixture thereof. 
Kompozicija u skladu sa zahtjevom 1, naznačena time što je nosač izabran iz grupe koju sačinjavaju mikrokristalna celuloza, trehaloza, inozitol, L-prolin u anhidridnom obliku, anhidridni dibazni kalcijev fosfat, anhidridna laktoza, laktoza monohidrat, izomalt, manitol ili njihova smjesa.
An inhalable pharmaceutical solution aerosol for use as claimed in claim 1, for maintaining lung function above 70% of baseline FEV1, or reducing the occurrences of lung function falling below 70% of baseline FEV1. 
Farmaceutska otopina aerosola za inhalaciju u skladu s patentnim zahtjevom 1, za održavanje funkcije pluća iznad 70% osnovne vrijednosti FEV,, ili smanjivanje pojave ispada funkcije pluća ispod 70% osnovne vrijednosti FEV,.
In certain embodiments, the renewable fuel oil may comprise a water content in the range of less than 40 wt. %, such as less than 35 wt. %, or less than 30 wt. %. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time što neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt. % i/ili manje od 0,1 wt. %.
The plant cultivation system according to claim 3, wherein said feeding means further comprises a water absorbing material which is disposed between said nonporous hydrophilic film and water impermeable material, and which is in contact with the lower surface of said nonporous hydrophilic film. 
Sustav za uzgoj biljaka prema zahtjevu 1, koji obuhvaća taj vodonepropusni materijal (2), i koji se, kada je u uporabi, postavlja na zemljano tlo na način da vodonepropusni materijal (2) bude u doticaju sa zemljanim tlom.
In one embodiment of the compounds of the Formula ID, the group R3 is (1-6C)alkyl, particularly unsubstituted (1-6C)alkyl. 
U jednoj izvedbi spojeva prikazan Formulom ID, skupina R? je (1-6C)alkil, najpoželjnije nezasićeni (1-6C) alkil).
coating a substrate with a liquid reactive composition which can be digitally printed on after drying; 
premazivanja podloge (2) tekućim reaktivnim pripravkom na koji se nakon sušenja može nanositi digitalni tisak;
detecting an Internet address of a multimedia content associated (R1,..., RN) erroneously to a first (T1) of said type (T1,..., TN) and detecting a second type (T2) to be associated to said Internet address; 
- - pronalaženje internetske adrese multimedijalnog sadržaja (RI,..., RN) pogrešno povezane s prvom (T1) od navedenih vrsta (T1,..., TN) te pronalaženje druge vrste (T2) koju povezati s navedenom internetskom adresom;
The process according to claim 1, wherein the amount of CO2 used, in mol, to produce 1 mol of the at least one earth alkali hydrogen carbonate in the aqueous solution is in the range of 0.5 to 4 mol of CO2. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time da je količina upotrijebljenog CO2, u mol, za dobivanje 1 mol barem jednog zemnoalkalijskog hidrogenkarbonata u vodenoj otopini u rasponu od 0.5 do 4 mol, poželjno u rasponu od 0.5 do 2.5 mol, poželjnije u rasponu od 0.5 do 1.0 mol, te najpoželjnije u rasponu od 0.5 do 0.65 mol.
ii) the fixed number in the horizontal direction has a fixed value of 2^5 and the dy number is determined from among {32, 26, 21, 17, 13, 9, 5, 2, 0, -2, -5, -9, -13, -17, -21, -26, -32} according to the intra prediction mode of the current block. 
Postupak za kodiranje slike, te postupak sadrži: provođenje intra predviđanja na trenutnom bloku u skladu s načinom intra predviđanja; dobivanje rezidualnih podataka koji pokazuju razliku između vrijednosti intra predviđanja i vrijednosti piksela trenutnog bloka;
is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl; 
je vodik, izborno supstituirani alkil, izborno supstituirani cikloalkil, izborno supstituirani cikloalkilalkil, izborno supstituirani aril, izborno supstituirani arilalkil, izborno supstituirani heterocikloalkil, izborno supstituirani heterocikloalkilalkil, izborno supstituirani heteroaril ili izborno supstituirani heteroarilalkil;
reaction (O-reac)is a reaction of a compound of formula (XXIII), with a reagent (O-reag); 
Kod reakcije (O-reak.) radi se o reakciji spoja formule (XXIII) s reagensom (O-reag.);
comparison of the calculated value with a predetermined value of the sign, 
- < usporedba (S4) izračunate vrijednosti s paritetom navedenog predznaka,
A composition suitable for control of diseases caused by phytopathogens comprising a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) the compound fenpropimorph. 
Postupak za kontrolu bolesti hrđe na biljkama soje, naznačen time, da se sastoji od primjene na korisne biljke, na njihov lokus ili na njihov materijal razmnožavanja, pripravka koji sadrži spoj formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo.
R2b and R2c are independently selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, fluorinated C1-C3 alkyl, cyano, C1-C3 alkoxy, and N(CH3)2; X is selected from the group consisting of 
je neovisno odabrana iz skupine koju čine halogen, C1-C3 alkil, fluorirani C1-C3 alkil, cijano, C1-C3 alkoksi i NR4R4', gdje R4 i R4' su neovisno odabrane iz skupine koju čine
to an activated cysteinamide through the Pro of the 2-6 eptifibatide sequence, thereby forming the 2-7 eptifibatide sequence. 
HR P20090490 T1 na aktivirani cisteinamidni ostatak preko Pro ostatka fragmenta 2-6 eptifibatida, da na taj način nastane fragment 2- 7 eptifibatida.
substituted or unsubstituted heterocyclyl, with the proviso that when Ra is amino, then X, Y, Z, and n together do not form a phenyl, 4-alkyl-phenyl, 4-alkoxy-phenyl, or 4-halo-phenyl group. 
supstituirani ili nesupstituirani heterociklil, pod uvjetom da kada je Raamino, tada X, Y, Z i n zajedno ne tvore fenil, 4-alkil-fenil, 4-alkoksi-fenil ili 4-halo-fenil skupinu.
Sugar and also salt are added to food products in order to bind water in the food products. 
Šećer, a i sol, dodaju se prehrambenim proizvodima da u njima vežu vodu.
It is also disclosed that the soaked ligno-cellulosic biomass stream may be separated by means of a compression screw. 
Proces iz bilo kojeg od patentnih zahtjeva 7 do 9, gdje struja natopljene ligno-celulozne biomase je odvojena posredstvom vijka za kompresiju.
AVI is a chalcogen of group VIA, or group 16 in the IUPAC nomenclature. 
A" je halkogen iz skupine VI, ili skupine 16 u IUPAC-ovoj nomenklaturi.
and ethyl acetate, the remaining solid fraction was removed by filtration and dried in vacuo. 
i etil acetat, preostala čvrsta frakcija se ukloni filtracijom i osuši u vakuumu.
X is selected from the group consisting of CO and SO2. 
Ar je odabran iz skupine koju čine:
An established cell line derived from a single cell is referred to as a clonal cell line An established cell line can be one whose cells endogenously express all component necessary for the cells to undergo the overall cellular mechanism whereby a BoNT/A proteolytically cleaves a SNAP-25 substrate and encompasses the binding of a BoNT/A to a BoNT/A receptor, the internalization of the neurotoxin/receptor complex, the translocation of the BoNT/A light chain from an intracellular vesicle into the cytoplasm and the proteolytic cleavage of a SNAP-25. 
PATENTNI ZAHTJEVI ka Postupak otkrivanja aktivnosti BoNT/A kod sisavca koji sadrži korake: a. = tretiranje stanice iz uspostavljene stanične linije koja eksprimira SNAP-25 testnim uzorkom koji sadrži BoNT/A, pri čemu je stanica iz uspostavljene stanične linije osjetljiva na intoksikaciju BoNT/A, pri čemu je stanica iz uspostavljene stanične linije osjetljiva na intoksikaciju BoNT/A od oko 500 pM ili manje BoNT/A i pri čemu je navedena stanica izabrana iz skupine koja se sastoji od SiMa stanične linije i Neuro-2a stanične linije; b.
From the foregoing it is apparent that the invention provides a wall element, in particular an outside wall element, which is durable, yet lightweight, fire resistant and easy to handle so that buildings may be constructed in an simple and quick manner. 
Iz ranije navedenog očito je da predmetni izum pruža zidni element, posebice vanjski zidni element, koji je postojan, a pored toga lagan, vatrootporan i jednostavan za rukovanje što bi omogućilo da se građevine grade na jednostavan i brz način.
An aqueous pharmaceutical composition comprising an enzyme which is a replacement for a lysosomal enzyme, a buffering agent, a surfactant and a tonicifier, for use in a method comprising a step of administering the composition intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of the lysosomal enzyme, characterized in that the composition has a pH of 5.5 to 7.0, the enzyme is present at a concentration of greater than about 10 mg/ml, and the buffering agent is up to 5 mM phosphate. 
Vodeni farmaceutski sastav koji sadrži enzim koji je zamjena za lizozomski enzim, pufer agens, surfaktant i tonikator, za upotrebu u metodi koja sadrži korak administriranja sastava intratekalno subjektu koji pati ili je podložan lizozomskim bolestima nakupljanja povezanih sa smanjenom razinom ili aktivnosti lizozomskog enzima naznačeno time da sastav ima pH od 5.5 do 7.0, enzim je prisutan u koncentraciji većoj od oko 10 mg/ml i pufer agens je do 5 mM fosfat.
TLC (4:1 chloroform-methanol) showed a single spot, Rf 0.5 (characteristic reaction with 4-dimethylamino benzaldehyde). 
TLC (4:1 kloroform-metanol) pokazuje jednu zonu, Rf 0,5 (karakteristična reakcija s 4-dimetilamino benzaldehidom).
A compound of formula I: 
L Spoj formule I
The method of claim 12, wherein the dose is 4 grams per day. A method of treating hypertriglyceridemia, comprising orally administering to a patient having pre-treatment serum or plasma triglyceride levels of about 200 mg/dL to about 500 mg/dL a therapeutically effective amount of a pharmaceutical composition and a therapeutically effective amount of a statin; wherein 
Farmaceutski pripravak sukladno patentnom zahtjevu 1, za liječenje hipertrigliceridemije kod pacijenata koji imaju vrijednosti triglicerida u serumu ili plazmi od 200 mg/dL do 500 mg/dL na terapiji statinom, pri čemu navedeno liječenje obuhvaća oralnu primjenu učinkovite količine statina i najmanje 2 g na dan farmaceutskog pripravka sukladno patentnom zahtjevu 1.
aluminum or aluminum alloys with magnesium, wherein the TGEC or the RIS additionally contain one or more soluble salts of Mn, Fe, Cr, Co, Ni or V. 
aluminija ili aluminijevih legura s magnezijem, u čemu TGEC ili RIS dodatno sadrže jednu ili više topivih soli od Mn, Fe, Cr, Co, Ni ili V.